Brain Health Observatory Country Studies

Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in the United States

Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in Canada

Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment

Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer’s disease treatment

Why would Canada have the longest wait times for an Alzheimer’s treatment among the G7 countries?

Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population

Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer’s Treatment

Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis

Why would Canada have the longest wait times for an Alzheimer’s treatment among the G7 countries?

Projected Ontario budget savings from reduced long-term care utilization due to a disease-modifying Alzheimer’s treatment

The age-specific comorbidity burden of mild cognitive impairment: a US claims database study

Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in the Eu-5 Countries

Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer’s Treatment

Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer’s Treatment

Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer’s Treatment

Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer’s Treatment

Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer’s Treatment

Expected wait times for access to a disease-modifying Alzheimer’s treatment in England: A modelling study

Estimates of Current Capacity for Diagnosing Alzheimer’s Disease in Sweden and the Need to Expand Specialist Numbers

Assessing the Preparedness of the Japanese Health Care System Infrastructure for an Alzheimer’s Treatment

Assessing the Preparedness of the Korean Healthcare System Infrastructure for an Alzheimer’s Treatment

Assessing the Preparedness of the Taiwanese Healthcare System Infrastructure for an Alzheimer’s Treatment

Is Korea Prepared for an Alzheimer’s Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests

Preparedness of China’s health care system to provide access to a disease-modifying Alzheimer’s treatment

Assessing the Preparedness of the Australian Health Care System Infrastructure for an Alzheimer’s Disease-Modifying Therapy

Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer’s disease treatment